PacBio (PACB) announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio’s HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Largest borrow rate increases among liquid names
- PacBio price target lowered to $1.25 from $2 at Piper Sandler
- PacBio board: Independent investigation concludes allegations unsubstantiated
- Pacific Biosciences: Strategic Shift to Long-Read Sequencing Fuels Buy Rating Amid Strong Q1 Performance
- Pacific Biosciences’ Earnings Call: Achievements and Challenges